中国生物工程杂志

［1］ Folkman J. Tumor angiogenesis: therapeutic implications. Engl N J Med, 1971, 285(21): 1182 1186. 
［2］Carmeliet P, Jain R K. Angiogenesis in cancer and other diseases. Nature, 2000, 407(6801): 249 257. 
［3］ Folkman J, Kalluri R. Cancer without disease. Nature, 2004, 427(6977): 787. 
［4］ Naumov G N, Folkman J, Straume O. Tumor dormancy due to failure of angiogenesis. Clin Ex PMetastasis, 2009, 26(1): 51 60. 
［5］ Folkman J, Shing Y. Angiogenesis. J Biol Chem, 1992, 267(16): 10931 10934. 
［6］ Folkman J. Angiogenesis dependent diseases. Semin Oncol, 2001, 28(6): 536 542. 
［7］ Kilarski W W, Gerwins P. A new mechanism of blood vessel growth hope for new treatment strategies. Discov Med, 2009, 8(40): 23 27. 
［8］ Cooke V G, Kalluri R. Molecular mechanism of type IV collagenderived endogenous inhibitors of angiogenesis. Methods Enzymol, 2008,444:1 19. 
［9］ Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res, 2005, 65(10): 3967 3979. 
［10］ Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov, 2007, 6(4): 273 286. 
［11］ Otrock Z K, Mahfouz R A, Makarem J A, et al. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis, 2007, 39(2): 212 220. 
［12］ Sund M, Hamano Y, Sugimoto H, et al. Function of endogenous inhibitors of angiogenesis as endothelium specific tumor suppressors . Proc Natl Acad Sci USA, 2005, 102(8): 2934 2939. 
［13］ Tsang K Y, Cheung M C, Chan D, et al. The developmental roles of the extracellular matrix: beyond structure to regulation. Cell and Tissue Res, 2010,339(1):93110. 
［14］ Rozario T, DeSimone D W. The extracellular matrix in development and morphogenesis: A dynamic view. Dev Biol, 2010,341(1):126140. 
［15］ Bauer A L, Jackson T L, Jiang Y. Topography of extracellular matrix mediates vascular morphogenesis and migration speeds in angiogenesis. PLoS Comput Biol, 2009,5(7): e1000445. 
［16］ Eduard M D, Akmal M D, Vachtang M D, et al. Promotion of tumor cell migration by extracellular matrix proteins in human pancreatic cancer . Pancreas, 2009, 38(7): 804 810. 
［17］ Kalluri R. Discovery of type Ⅳ collagen noncollagenous domains as novel integrin ligands and endogenous inhibitors of angiogenesis. Cold Spring Harb Sym PQuant Biol, 2002, 67: 255 266. 
［18］ Sugimoto M, Oohashi T, Ninomia Y. The genes COL4A5 and COL4A6, coding for the basement membrane collagen chains α5(IV) and α6(IV), are located head to head in close proximity on human chromosome Xq22 and COL4A6 is transcribed from two alternative promoters. Proc Natl Acad Sci USA, 1994, 91(24): 11679 11683. 
［19］ Colorado P C, Torre A, Kamphaus G, et al. Anti angiogenic cues from vascular basement membrane collagen. Cancer Res, 2000, 60(9): 2520 2526. 
［20］ Sudhakar A, Nyberg P, Keshamouni V G, et al. Human α1 type Ⅳ collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin. J Clin Invest, 2005, 115(10): 2801 2810. 
［21］ Kamphaus G D, Colorado P C, Panka D J, et al. Canstatin, a novel matrix derived inhibitor of angiogenesis and tumor growth. J Biol Chem, 2000, 275(2): 1209 1215. 
［22］ Panka D J, Mier J W. Canstatin inhibits Akt activation and induces Fas dependent apoptosis in endothelial cells. J Biol Chem, 2003, 278(39): 37632 37636. 
［23］ Magnon C, Galau P A, Mullan B, et al. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with αvβ3 and αvβ5 integrins. Cancer Res, 2005, 65(10): 4353 4361. 
［24］ Maeshima Y, Colorado P C, Torre A, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem, 2000, 275(28): 21340 21348. 
［25］ Maeshima Y, Colorado P C, Kalluri R.Two RGD independent αvβ3 integrin binding sites on tumstatin regulate distinct anti tumor properties. J Biol Chem, 2000, 275(31): 23745 23750. 
［26］ Maeshima Y, Yerramalla U L, Dhanabal M, et al. Extracellular matrix derived peptide binds to αvβ3 integrin and inhibits angiogenesis. J Biol Chem, 2001, 276(34): 31959 31968. 
［27］ Maeshima Y, Sudhakar A, Lively J C, et al. Tumstatin, an endothelial cell specific inhibitor of protein synthesis. Science, 2002, 295(5552): 140 143. 
［28］ Sudhakar A, Boosani C S. Inhibition of tumor angiogenesis by tumstatin: insights into signaling mechanisms and implications in cancer regression. Pharm Res, 2008, 25(12): 2731 2739. 
［29］ Boosani C S, Mannam A P, Cosqrove D, et al. Regulation of COX 2 mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis. Blood, 2007, 110(4): 1168 1177. 
［30］ 温镭，贺欣，赵启仁,等．新型肿瘤血管生成抑制剂hexastatin的研究进展．中国肿瘤生物治疗杂志，2009,16(5):537 540. Wen L, He X, Zhao Q R, et al. Chinese Journal of Cancer Biotherapy, 2009,16(5): 537 540. 
［31］ Karagiannis E D, Popel A S. Identification of novel short peptides derived from the α4, α5, and α6 fibrils of type IV collagen with anti angiogenic properties. Biochem Biophys Res Commun, 2007,354(2): 434 439. 
［32］ Petitclerc E, Boutaud A, Prestayko A, et al. New functions for non collagenous domains of human collagen: type IV novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem, 2000, 275(11): 8051 8061. 
［33］ Baba Y, Iyama K, Ikeda K, et al. Differential expression of basement membrane type IV collagen α chains in gastric intramucosal neoplastic lesions. J Gastroenterol, 2007, 42(11): 874 880. 
［34］ Nyberq P, Xie L, Suqimoto H, et al. Characterization of the anti angiogenic properties of arresten, an α1β1 integrin dependent collagenderived tumor suppressor. Exp Cell Res, 2008, 314(18): 3292 3305. 
［35］ Long M Y, Li H H, Xu J Y, et al. Inhibitory effects of transfection of arresten gene on liver metastasis from colorectal cancer in nude mice. Ai Zheng, 2008, 27(10): 1039 1043. 
［36］ Narazaki M, Tosato G. Canstatin: an inhibitor of angiogenesis and tumor growth revisited. Cancer J, 2006, 12(2): 110 112. 
［37］ Lee J H, Lee J M, Jeon H B, et al. Expression and in vitro activity of recombinant canstatin in stably transformed bombyx mori cells. J Microbiol Biotechnol, 2009, 19(7): 685 689. 
［38］ Wang W B, Zhou Y L, Heng D F, et al. Combination of tumor necrosis factor related apoptosis inducing ligand(TRAIL) and canstatin gene suppression therapy on breast tumor xenograft growth in mice. Breast Cancer Res Treat, 2008, 110(2): 283 295. 
［39］ Zheng X W, Li Y, Tang F A, et al. In vivo antitumor effect of canstatin gene on human esophageal carcinoma xenografts in nude mice. Ai Zheng, 2009, 28(4): 350 355. 
［40］ Magnon C, Opolon P, Connault E, et al. Canstatin gene electrotransfer combined with radiotherapy: preclinical trials for cancer treatment. Gene Ther, 2008, 15(21): 1436 1445. 
［41］ Hamano Y, Kalluri R. Tumstatin, the NC1 domain of α3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem Biophys Res Commun, 2005, 333(2): 292 298. 
［42］ Caudroy S, Cucherousset J, Lorenzato M, et al. Implication of tumstatin in tumor progression of human bronchopulmonary carcinomas. Human Pathol, 2004, 35(10): 1218 1222. 
［43］ Pasco S, Brassart B, Ramont L, et al. Control of melanoma cell invasion by type IV collagen. Cancer Detect Prevent, 2005, 29(3): 260 266. 
［44］ Kawaguchi T, Yamashita Y, Kanamori M, et al. The PTEN/Akt pathway dictates the direct αvβ3 dependent growth inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res, 2006, 66(23): 11331 11340. 
［45］ Zhang X, Xu W, Qian H, et al. Mesenchymal stem cells modified to express lentivirus TNFα Tumstatin45 132 inhibit the growth of prostate cancer. J Cell Mol Med, in Press. 
［46］ Chung I S, Son Y I, Ko Y J, et al. Peritumor injections of purified tumstatin delay tumor growth and lymphatic metastasis in an orthotopic oral squamous cell carcinoma model. Oral Oncol, 2008, 44(12): 1118 1126. 
［47］ Maeshima Y, Manfredi M, Reimer C, et al. Identification of the antiangiogenic site within vascular basement membrane derived tumstatin. J Biol Chem, 2001, 276(18): 15240 15248. 
［48］ Eikesdal H P, Sugimoto H, Birrane G, et al. Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. Proc Natl Acad Sci USA, 2008, 105(39): 15040 15045. 
［49］ Zhang G M, Zhang Y M, Fu S B, et al.Effects of cloned tumstatin related and angiogenesis inhibitory peptides on proliferation and apoptosis of endothelial cells. Chin Med J, 2008, 121(22): 2324 2330. 
［50］ Li Y J, Sun L C, He Y, et al. The anti tumor properties of two tumstatin peptide fragments in human gastric carcinoma. Acta Pharmacol Sin, 2009, 30(9): 1307 1315. 
［51］ Zhou J, Mochizuki T, Smeets H, et al. Deletion of the paired α5(IV) and α6(IV) collagen genes in inherited smooth muscle tumors. Science, 1993, 261(5125): 1167 1169. 
［52］ Mundel T M, Yliniemi A M, Maeshima Y, et al. Type IV collagen α6 chain derived noncollagenous domain 1 (α6(IV)NC1) inhibits angiogenesis and tumor growth. Int J Cancer, 2008, 122(8): 1738 1744. 
［53］ Baba Y, Iyama K, Ikeda K, et al. The expression of type IV collagen α6 chain is related to the prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol, 2008, 15(2): 555 565. 
［54］ Ikeda K, Iyama K, Ishikawa N, et al. Loss of expression of type IV collagen α5 and α6 chains in colorectal cancer associated with the hypermethylation of their promoter region. Am J Pathol, 2006, 168(3): 856 865. 
［55］ Misumi S, Iyama K, Honda Y, et al. Differential expression of basement membrane type IV collagen α1, α2, α5 and α6 chains among the histological subtypes of adenoid cystic carcinoma. Virchows Arch, 2004, 445(1): 54 62. 
［56］ Stommel J M, Kimmelman A C, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 2007, 318(5848): 287 290.